Evotec SE ADR (EVO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Evotec SE ADR stock (EVO) is currently trading at $2.52. Evotec SE ADR PS ratio (Price-to-Sales) is 1.15. Analyst consensus price target for EVO is $5.24. WallStSmart rates EVO as Sell.
- EVO PE ratio analysis and historical PE chart
- EVO PS ratio (Price-to-Sales) history and trend
- EVO intrinsic value — DCF, Graham Number, EPV models
- EVO stock price prediction 2025 2026 2027 2028 2029 2030
- EVO fair value vs current price
- EVO insider transactions and insider buying
- Is EVO undervalued or overvalued?
- Evotec SE ADR financial analysis — revenue, earnings, cash flow
- EVO Piotroski F-Score and Altman Z-Score
- EVO analyst price target and Smart Rating
Evotec SE ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Evotec SE ADR (EVO) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Evotec SE ADR (EVO) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Good growth relative to its price
Paying $1.15 for every $1 of annual revenue
Supporting Valuation Data
Evotec SE ADR (EVO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -11.40%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 2.63%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Evotec SE ADR (EVO) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, PEG Ratio, Price/Sales. Valuation metrics including PEG Ratio (1.42), Price/Sales (1.15), Price/Book (0.94) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -11.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -18.00%, Operating Margin at -26.60%, Profit Margin at -21.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -18.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -11.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EVO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EVO's Price-to-Sales ratio of 1.15x trades at a deep discount to its historical average of 22.95x (2th percentile). The current valuation is 98% below its historical high of 72.03x set in Sep 2017, and 56% above its historical low of 0.74x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Evotec SE ADR (EVO) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Evotec SE ADR is in a turnaround phase, with management focused on restoring profitability. Revenue reached 756M with 11% decline year-over-year. The company is currently unprofitable, posting a -21.0% profit margin.
Key Findings
Revenue contracted 11% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -21.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Evotec SE ADR.
Bottom Line
Evotec SE ADR is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:23 AM
About Evotec SE ADR(EVO)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Evotec SE is a leading global biotechnology company based in Hamburg, Germany, renowned for its comprehensive drug discovery and development solutions tailored for the pharmaceutical and biotech industries. The firm utilizes a collaborative model, partnering with various stakeholders—ranging from established pharmaceutical companies to innovative academic institutions—to propel the advancement of therapeutic programs across numerous modalities, including small molecules, biologics, and cell therapies. With a robust pipeline of projects and a steadfast focus on enhancing patient outcomes, Evotec is well-positioned to capitalize on emerging opportunities in the biopharmaceutical sector, solidifying its pivotal role in driving healthcare innovation.